US20150306158A1 - Lactic acid bacteria capable of preventing and/or treating senescence and dementia - Google Patents

Lactic acid bacteria capable of preventing and/or treating senescence and dementia Download PDF

Info

Publication number
US20150306158A1
US20150306158A1 US14/421,714 US201314421714A US2015306158A1 US 20150306158 A1 US20150306158 A1 US 20150306158A1 US 201314421714 A US201314421714 A US 201314421714A US 2015306158 A1 US2015306158 A1 US 2015306158A1
Authority
US
United States
Prior art keywords
dementia
strain
lactobacillus
induced
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/421,714
Other languages
English (en)
Inventor
Dong-Hyun Kim
Myung Joo Han
Il-Hoon Jung
Myung-Ah Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Kyung Hee University
Original Assignee
Industry Academic Cooperation Foundation of Kyung Hee University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Kyung Hee University filed Critical Industry Academic Cooperation Foundation of Kyung Hee University
Assigned to UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY reassignment UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAN, MYUNG JOO, JUNG, IL-Hoon, JUNG, Myung-Ah, KIM, DONG-HYUN
Publication of US20150306158A1 publication Critical patent/US20150306158A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C12R1/225—
    • C12R1/25—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Definitions

  • the present invention relates to a novel lactic acid bacterium isolated from Kimchi, and more specifically, relates to novel Lactobacillus pentosus var. plantarum C29 and Lactobacillus curvatus C3 having an activity for preventing and/or treating aging (senescence) and dementia.
  • a process progressing the aging is affected by a genetic, environment, and complex action of a lifestyle, and is followed by various morphological, biochemical changes, in particular, an increase of oxidation stress and inflammation reaction are believed as a major reason involving in a promotion of aging.
  • the oxidation stress is caused by an increase of a generation of reactive oxygen species having a strong reactivity or a reduction of an anti-oxidative defense mechanism in a body, and as a result, biomacromolecules such as DNA, etc. are destroyed, cellular damages are caused to promote the aging, and a risk of age-associated diseases, such as degenerative neuronal disease including dementia, cancer, cardiovascular diseases, etc. is increased.
  • Dementia which is one of aging diseases is occurred by chronic or progressive diseases of brain, and regression, degeneration of brain tissues, and aging-central nervous system infection (neurosyphilis, tuberculous meningitis, viral encephalitis, etc.), cerebral infarction, brain damage, toxic metabolic disorder, nervous system disease (Parkinson's disease) and the like, have been known to be a major reason for causing the dementia.
  • Dementia includes Alzheimer's disease, vascular dementia, and other mixed forms, 50 ⁇ 60% of old dementia patients aged 65 or more have Alzheimer's dementia and remaining 10 ⁇ 15% of them have the mixed forms of such two (2) diseases.
  • ⁇ -amyloid A ⁇
  • acetylcholinesterease inhibitor which acts in acetylcholine, is used as a treating agent, but it is known that it partially exhibits an improvement of a cognitive function but does absolutely no action in proceeding of Alzheimer's disease. And thus, there is a need for a development of the effective agent for preventing or treating dementia.
  • lactic acid bacteria have been used for a long time and their intestinal regulations, anticancer effects, immune boost effects and the like have been reported. Therefore, inventors of the present invention had been studied for searching lactic acid bacteria having beneficial effects in aging and dementia, and as a result, confirmed that novel lactic acid bacteria isolated from Kimchi have effects for preventing or treating aging and dementia and then completed the present invention.
  • An object of the present invention is to provide lactic acid bacteria having effects for preventing or treating an aging and dementia.
  • Another object of the present invention is to provide an antioxidant and anti-aging composition and a composition for preventing or treating dementia, which include the lactic acid bacteria.
  • Still another object of the present invention is to provide an antioxidant and anti-aging fermentation composition, and a fermentation composition for preventing or treating dementia, which are fermented with the lactic acid bacteria.
  • the present invention provides Lactobacillus pentosus var. plantarum C29 KCCM11291P isolated from Kimchi.
  • the present invention provides an antioxidant and anti-aging pharmaceutical composition including Lactobacillus pentosus var. plantarum C29 as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating dementia, which includes Lactobacillus pentosus var. plantarum C29 as an active ingredient.
  • the present invention provides a health dietary supplement having antioxidant and anti-aging effects, which includes Lactobacillus pentosus var. plantarum C29 as an active ingredient.
  • the present invention provides a health dietary supplement for preventing or improving dementia, which includes Lactobacillus pentosus var. plantarum C29 as an active ingredient.
  • the present invention provides an antioxidant and anti-aging composition including a fermentation composition, which is fermented with Lactobacillus pentosus var. plantarum C29, as an active ingredient.
  • the present invention provides a composition for preventing or treating dementia, which includes a fermentation composition that is fermented with Lactobacillus pentosus var. plantarum C29, as an active ingredient.
  • the present invention provides Lactobacillus curvatus C3 KCCM43009 isolated from Kimchi.
  • the present invention provides an antioxidant and anti-aging pharmaceutical composition including Lactobacillus curvatus C3 as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating dementia, which includes Lactobacillus curvatus C3, as an active ingredient.
  • the present invention provides a health dietary supplement having antioxidant and anti-aging effects, which includes Lactobacillus curvatus C3, as an active ingredient.
  • the present invention provides a health dietary supplement for preventing or improving dementia, which includes Lactobacillus curvatus C3, as an active ingredient.
  • the present invention provides an antioxidant and anti-aging composition including a fermentation composition, which is fermented with Lactobacillus curvatus C3, as an active ingredient.
  • the present invention provides a composition for preventing or treating dementia, which includes a fermentation composition that is fermented by Lactobacillus curvatus C3, as an active ingredient.
  • Lactobacillus pentosus var. plantarum C29 and Lactobacillus curvatus C3 of the present invention are novel microorganisms isolated from cabbage Kimchi.
  • the Lactobacillus pentosus var. plantarum C29 of the present invention is a strain belonging to lactobacillus in a molecular phylogenetic systematic and biochemical characteristic analysis based on 16s rDNA base sequence and was identified as the strain exhibiting a high level of the molecular phylogenetic systematic relationship with both of Lactobacillus pentosus and Lactobacillus plantarum , but since its biochemical characteristics were more similar to those of Lactobacillus pentosus , it was called as Lactobacillus pentosus var. plantarum C29, and deposited on the International Depository Authority, Korean Culture Center of Microorganisms(“KCCM”) as a Deposit No. KCCM1129P, on Jul. 9, 2012.
  • Lactobacillus curvatus C3 of the present invention is a strain belonging to lactobacillus in the molecular phylogenetic systematic analysis based on 16s rDNA base sequence, and was identified as the strain belonging to Lactobacillus curvatus , and thus, it was called as Lactobacillus curvatus C3, and deposited on the International Depository Authority, KCCM as a Deposit No. KCCM43009, on Jul. 9, 2012.
  • the Lactobacillus pentosus var. plantarum C29 (hereinafter, also referred to as “C29”) and the Lactobacillus curvatus C3 (hereinafter, also referred to as “C3”) of the present invention were identified as having effects on improving a memory of mice by a passive avoidance response test using an animal model, mouse with Alzheimer's disease when the C29 strain or C3 strain is administered, and the C29 strain was also identified as having the memory improvement effect even in a Y maze task and a water maze task, and thus, these effects on preventing and treating dementia were confirmed (See Example 2).
  • dementia refers to the state, in which a brain function is damaged by various reasons, and also a cognitive function such as a memory, linguistic skills, and judgments is consistently and generally lowered than ever before thereby exhibiting the negative effects in the daily life, and includes senile dementia, Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's dementia, Huntington's dementia, dementia induced by normal pressure hydrocephalus, dementia induced by a head injury, dementia induced by a material, and the like.
  • Lactobacillus pentosus var. plantarum C29 and Lactobacillus curvatus C3 of the present invention were identified as being strains having superior effects for preventing and treating dementia and an aging.
  • the morphological features, the physiological features, the analysis results of the sucrose fermentation, and the composition of cellular fatty acid of the Lactobacillus pentosus var. plantarum C29 of the present invention are listed with the features of the known L. plantarium ATCC 14917 and L. pentosus DSM20314, in the following Tables 1, 2 and 3.
  • the Lactobacillus pentosus var. plantarum C29 strain and Lactobacillus curvatus C3 strain of the present invention may be used for preventing and treating aging and dementia, and thus, the present invention provides an antioxidant and anti-aging pharmaceutical composition and a pharmaceutical composition for preventing or treating dementia, which include a Lactobacillus pentosus var. plantarum C29 strain or a Lactobacillus curvatus C3 strain as an active ingredient.
  • the pharmaceutical composition of the present invention may be administered orally (e.g., taking medicine by mouth or inhalation) or parenterally (e.g., injection, percutaneous absorption, or rectal administration), and the injection may be, for example, a venous injection, a subcutaneous injection, an intramuscular injection, or an intraperitoneal injection.
  • the pharmaceutical composition according to the present invention may be formulated into a tablet, capsule, granule, fine subtilae, powder, sublingual tablet, suppository, ointment, injection, turbid liquid, suspension, syrup, spray, and the like, according to an administration route.
  • compositions according to the present invention in the above-described various forms may be prepared by the known techniques using a pharmaceutical acceptable carrier that is generally used for each of the formulations.
  • a pharmaceutical acceptable carrier include an excipient, binding agent, disintegrating agent, lubricant, preservative, antioxidant, isotonic agent, buffer, coating agent, sweetening agent, solubilizer, base, dispersion, wetting agent, suspending agent, stabilizer, colorant, and the like.
  • the pharmaceutical composition according to the present invention includes the Lactobacillus pentosus var. plantarum C29 strain or Lactobacillus curvatus C3 strain of the present invention in the amount of about 0.01 to 100 wt %, depending on their pharmaceutical formulations.
  • the specific dose of the pharmaceutical composition of the present invention may be varied according to a kind, a body weight, a sex, a degree of the disease of a mammal including a human to be treated, a decision of a practitioner, and the like, and the proper dose according to the specific use may be determined by the person ordinary skilled in the art.
  • 0.001 to 500 mg of an active ingredient per 1 kg of a body weight per a day is administered, and for a parenteral administration, 0.01 to 200 mg of an active ingredient per 1 kg of a body weight per a day is administered. More preferably, 100 mg of an active ingredient per 1 kg of a body weight per a day is administered.
  • the total dose per a day may be administered at one time or several times depending on a degree of a disease, a judgment by a practitioner and the like.
  • the present invention also provides a health dietary supplement having an antioxidant and anti-aging effects and a health dietary supplement for preventing or improving dementia, which includes a C29 strain or a C3 strain as an active ingredient.
  • a kind of the health dietary supplement of the present invention is not specifically limited, and the health dietary supplement of the present invention may be in a form of an oral-type formulation, such as, a powder, granule, table, capsule, suspension, emulsion, and syrup, or may be added to a general food, such as, a candy, cracker, gum, ice cream, noodle, bread, and beverage.
  • an oral-type formulation such as, a powder, granule, table, capsule, suspension, emulsion, and syrup
  • a general food such as, a candy, cracker, gum, ice cream, noodle, bread, and beverage.
  • the health dietary supplement of the present invention may be prepared by properly using a filler, extender, binder, wetting agent, disintegrating agent, sweetening agent, flavoring agent, preservative, surfactant, lubricant, excipient, and the like in a routine manner according to its forms.
  • the content of a C29 strain or C3 strain for the preparation of the above-described health dietary supplement is different according to a form of a health dietary supplement, but the content thereof may be approximately 0.01 to 100 wt %.
  • the present invention provides a composition having an antioxidant and anti-aging effect and a composition for preventing or improving dementia, which include a fermentation composition that is fermented with a C29 strain or C3 strain, as an active ingredient.
  • the fermentation composition includes a fermentation composition of a soybean or defatted soybean, a fermentation composition of kalopanax , a fermentation composition of ginseng, and a fermentation composition of condonopsis lanceolata.
  • a water suspension of the powder of the soybean or defatted soybean means to one prepared by adding 5 to 15 times water to the powder's weight to the powder of the dried soybean or defatted soybean and suspending the powder in the water, but the present invention is not limited thereto.
  • a type of soybean milk prepared by grinding the soybean soaked in water may be used, as long as it corresponds to the objects of the present invention.
  • the kalopanax , ginseng and condonopsis lanceolata may be in a form of an extract or essence, and preferably, a type of the extract prepared by a hydrothermal extraction, ethyl alcohol extraction or mixed extraction may be used, but the present invention is not limited thereto.
  • a type of the extract prepared by a hydrothermal extraction, ethyl alcohol extraction or mixed extraction may be used, but the present invention is not limited thereto.
  • it may be ground or powdered, and the grinding and pulverization process may be conducted according to the conventional extraction method well-known in the art.
  • a water extraction method, alcohol extraction method, organic solvent extraction method and supercritical extraction method, and the like may be used, and preferably the water extraction method is used, but the present invention is not limited thereto.
  • an extraction solvent used in the above-described alcohol extraction method low alcohol having 1 to 6 carbon atoms, and the like, such as methanol, ethanol, propanol, isopropanol, and butanol, may be used, and as an extraction solvent used in the above-described organic solvent extraction method, an organic solvent such as acetone, ether, benzene, chloroform, ethylacetate, methylene chloride, hexane, hydrochloric acid, acetic acid, formic acid, citric acid, cyclohexane and petroleum ether; or a mixture thereof may be used.
  • an organic solvent such as acetone, ether, benzene, chloroform, ethylacetate, methylene chloride, hexane, hydrochloric acid, acetic acid, formic acid, citric acid, cyclohexane and petroleum ether; or a mixture thereof may be used.
  • the rate of the extraction solvent added at the time of extraction is not specifically limited, but 2 to 20 times (based on the weight) of the extraction solvent with respect to the dry weight of kalopanax , ginseng, or condonopsis lanceolata may be used.
  • the extraction may be repeated several times, for example, 2 times or more by using 5 times to 15 times (based on the weight) of the extraction solvent with respect to kalopanax , ginseng or condonopsis lanceolata.
  • an extraction temperature is preferably 50 to 110° C., and more preferably, 70 to 100° C.
  • An extraction time varies according to the extraction temperature, but may be 1 to 48 hours, and preferably 2 to 8 hours. In addition, when it is stirred with a shaker at the time of extraction, the extraction efficiency may be more increased.
  • the extract may be prepared by a decompression distillation method or thin film distillation method.
  • the effects of the soybean or defatted soybean fermentation composition fermented by inoculating a C29 strain or C3 strain, the kalopanax fermentation composition, the ginseng fermentation composition, and the condonopsis lanceolata fermentation composition on improving the memories of mice are confirmed in a passive avoidance response task by using the mice, an animal model with Alzheimer's disease, and thus, the effects for preventing or treating dementia are confirmed (see Example 5).
  • the extract when the C29 strain or C3 strain is inoculated on the above-described extract, the extract is used after heating the extract at the temperature of 100° C. or more for 15 minute to 1 hour for a sterilization to inhibit the growth of spoilage bacteria at the time of the inoculation.
  • the inoculating amount of the C29 strain or C3 strain varies according a kind of the extract used in the fermentation, the inoculating amount thereof is to be 1 ⁇ 10 8 CFU/ml or more and a fermentation temperature is preferably 20 to 40° C.
  • a fermentation time is not specifically limited as long as it corresponds to the objects of the present invention, the fermentation time may be 10 to 30 hours after inoculating the C29 strain or C3 strain. In this case, when it is fermented for 10 hours or more, the fermentation composition is not sufficiently made, and when it is fermented for 30 hours and more, an organic acid is made much so as to generate strong sour taste and thus decrease a mouthfeel, and therefore, it is preferable to ferment it within the range of the fermentation time as mentioned above.
  • various fermentation food may be prepared according to the materials used in the fermentation; and for example, a fermentation beverage of lactic acid bacteria such as a yogurt may be prepared by inoculating a C29 strain or C3 strain to dry milk or milk, and then, fermenting it by the manner as above.
  • a fermentation beverage of lactic acid bacteria such as a yogurt may be prepared by inoculating a C29 strain or C3 strain to dry milk or milk, and then, fermenting it by the manner as above.
  • the Lactobacillus pentosus var. plantarum C29 strain or Lactobacillus curvatus C3 strain of the present invention has the superior effects on preventing and improving aging and dementia, and thus, they can be usefully utilized in the prevention or treatment of aging and dementia. Therefore, the pharmaceutical composition and the health dietary supplement including the Lactobacillus pentosus var. plantarum C29 strain or Lactobacillus curvatus C3 strain of the present invention can be effectively used for preventing or treating aging and dementia. Since the strains which are present in Kimchi intaken routinely are an active ingredient, it can be used without any concern for side effects or toxicity.
  • the fermentation compositions are prepared by inoculating the Lactobacillus pentosus var. plantarum C29 strain or Lactobacillus curvatus C3 strain of the present invention, they can be effectively utilized as the compositions for preventing or treating aging and dementia.
  • FIG. 1 illustrates the 16S rDNA sequence of C29 lactic acid strain (SEQ ID NO. 1).
  • FIG. 2 is a phylogenetic tree illustrating a position of Lactobacillus pentosus var. plantarum C29.
  • FIG. 3 is a graph illustrating the results of a passive avoidance response task.
  • FIG. 4 is a graph illustrating the effect of a C29 strain on improving memory that is increased in a concentration-dependent manner.
  • FIG. 5 is a gel photograph illustrating the effect of a C29 strain on improving memory.
  • FIG. 6 is a graph illustrating the results of a Y-maze task in Example 2.
  • FIG. 7 is a graph illustrating the result of a water maze task in Example 2, in which a black square represents scopolamine+(1 ⁇ 10 9 colony forming unit (CFU)/mouse C29), a white square represents scopolamine+(1 ⁇ 10 10 colony forming unit (CFU)/mouse C29), a black triangle represents scopolamine+(10 mg/kg of tacrine positive control drug), a white circle represents only scopolamine, and a black circle represents the normal control mice.
  • FIG. 8 is a gel photograph illustrating a change in an amount of the expression of aging-associated gene phosphate according to the administration of a C29 strain.
  • FIG. 9 is a graph illustrating the results of a Y maze task in Example 3, in which Y represents the young mice, O represents the aged mice, O/C29 represents the aged mice administered with C29 lactic acid bacteria (1 ⁇ 10 9 colony forming unit (CFU)/mouse), O/C3 represents the aged mice administered with C3 lactic acid bacteria (1 ⁇ 10 9 colony forming unit (CFU)/mouse), and O/C24 represents the aged mice administered with C24 lactic acid bacteria (1 ⁇ 10 9 colony forming unit (CFU)/mouse).
  • CFU colony forming unit
  • CFU colony forming unit
  • FIG. 10 is a graph illustrating the results of a water maze task in Example 3, in which Y represents the young mice, O represents the aged mice, O/C29 represents the aged mice administered with C29 lactic acid bacteria (1 ⁇ 10 9 colony forming unit (CFU)/mouse), O/C3 represents the aged mice administered with C3 lactic acid bacteria (1 ⁇ 10 9 colony forming unit (CFU)/mouse), and O/C24 represents the aged mice administered with C24 lactic acid bacteria (1 ⁇ 10 9 colony forming unit (CFU)/mouse).
  • FIG. 11 illustrates 16S rDNA sequence (SEQ ID NO. 2) of C3 lactic acid bacteria.
  • FIG. 12 is a graph illustrating the cognitive function-improvement effect of the fermentation composition fermented by a C29 strain or C3 strain.
  • Cabbage Kimchi was suspended in MRS broth, the supernatant thereof was inoculated on MRS agar medium, and then, the medium thereof was anaerobically cultured at a temperature of 37° C. for 24 hours. Since then, the colony being grown out was selected and gram-stained, and 16S rDNA thereof was analyzed, and then a lactobacillus strain was isolated.
  • human feces were suspended in GAM broth (Nissui Pharmaceutical Company, Ltd., Japan), the supernatant thereof was inoculated on BL agar medium (Nissui Pharmaceutical) and then, the medium thereof was anaerobically cultured at 37° C. for 48 hours. Since then, the colony being grown out was selected and gram-stained, and 16S rDNA thereof was analyzed, and then, the lactobacillus and Bifidobacterium strains were isolated.
  • the isolated strains are as follows:
  • mice All animals used in the experiment were the male ICR-based mice (28 to 30 g), and the experiment was performed in accordance with Guide for the Care and Use of Laboratory Animal (NIH publication No. 85-23). 5 and 6 laboratory animals were housed in a cage and were leaved to freely access to the food. The temperature in the cage was 23 ⁇ 1° C., the moisture was 60 ⁇ 10%, and 12 hours of day and night (07:30 ⁇ 19:30) were always maintained.
  • the latencies until the mouse enters into the dark section like this were determined and compared for the control and test groups.
  • the maximal limitation time was set to 300 seconds, wherein if the mouse did not enter into the dark section until over 300 seconds, the passive avoidance response latency was determined as 300 seconds. It was determined that greater the time until the animal passes over the dark section and the entrance was closed, the memory for passive avoidance through learning was well remained.
  • C1 to C30 lactic acid bacteria used in the experiment were administered to the animal model with dementia in a number of 1 ⁇ 10 10 CFU one per 1 day for 2 days.
  • Scopolamine (0.9 mg/kg) was administered at 1 hour after the last administration of lactic acid bacteria.
  • C29 of lactic acid bacteria used in the experiment best maintained the memory for the passive avoidance and exhibited the effects superior to Tacrin (TAC, 10 mg/kg), the treating agent of dementia, and it was the order of C3, and then C24.
  • C29 lactic acid bacteria identified as having the best effects were administered to the mouse in 1 ⁇ 10 9 and 1 ⁇ 10 10 CFU one per 1 day for two (2) days. Scopolamine (0.9 mg/kg) was administered at one hour after the last administration of lactic acid bacteria. As a result, as identified in FIG. 4 , C29 exhibited the effects in a concentration-dependent manner.
  • hippocampus of a brain was isolated and was homogenized by adding 100 ⁇ g of RIPA buffer (Gibco) with protease inhibitor cocktail. After centrifuging it at 4° C., 13000 rpm for 15 minutes, p-CREB, CREB, BDNF and ⁇ -actin were measured by an immunoblotting method, while the supernatant was stored at ⁇ 80° C.
  • the supernatant was taken and subjected to an electrophoresis on SDS 10% (w/v) polyacrylamide gel for an hour and a half (sample, 50 ⁇ g).
  • the gel subjected to electrophoresis was transferred onto a nitrocellulose paper at 100 V, 400 mA for 1 hour and 10 minutes, the transferred nitrocellulose paper was blocked by 5% defatted milk for 30 minutes and then washed with PBS-Tween three times each of 5 minutes, was reacted with the first antibody (Santa Cruz Biotechnology, USA) as 1:100 overnight. And then, after washing it three times with each of 10 minutes, the secondly antibody (Santa Cruz Biotechnology, USA) was reacted as 1:1000 for 1 hour and 20 minutes.
  • a Y-maze task measuring equipment had a shape of alphabet Y extending three arms, in which all the branches had 25 cm of a length, 14 cm of a height, and 5 cm of a width, and were positioned in the same angle.
  • a head part of the laboratory animal is headed for the end of a path of Y-maze and let it go around a passage freely for 8 minutes. After recording a movement of the animal, if hind legs of the animal entered the passage, it is considered that the animal is arm entry.
  • the movement of the animal is represented by an alternation, which is defined that if the animal passes three (3) passages continuously, it is defined as being one alternation.
  • An amount of a spontaneous alternation is represented by a percent of the real alternation and the maximal possible alternation (i.e., a value obtained by deducting 2 from the total alternation).
  • the C29 which is the best one of lactic acid bacteria used in the experiments was administered to the mouse in 1 ⁇ 10 9 and 1 ⁇ 10 10 CFU one per 1 day for two (2) days. Scopolamine (0.9 mg/kg) was administered at one hour after the last administration of lactic acid bacteria.
  • test group administered by the C29 exhibited the memory improvement effect in a concentration-dependent manner as compared with the control administered by scopolamine only.
  • the mouse found the platform, it is allowed to stay for 10 sec, and back to the original cage, and after 5 min, the next trial was practiced. If the mouse did not find the platform within 120 sec, it is allowed to stay in the platform for 10 sec, and then finished the trial. A probe test was practiced to the animal that the trial was finished at 24 hrs after the final trial. At this time, the platform was removed from the pool, and the time staying in the 4-divided circle that the platform was placed during 90 sec was measured to represent it as a percentage.
  • a swimming time was measured daily while administering the best C29 lactic acid bacteria in the amount of 1 ⁇ 10 9 and 1 ⁇ 10 10 CFU among the lactic acid bacteria used in the experiment once per day for 4 days.
  • Scopolamine (0.9 mg/kg) was administered at 1 hour after the first administration.
  • the C29 lactic acid bacteria exhibited the memory improvement effect in a concentration-dependent manner, as can be seen in FIG. 7 .
  • lactic acid bacteria C29, C3, C24 (1 ⁇ 10 9 CFU, respectively) were administered for five days for 12 weeks, and the anti-aging effect of the lactic acid bacteria and aging-associated gene AKT, FOXO3, NF- ⁇ B (p65), mTorr phosphate body in a large intestine that the progress of oxidation reaction is fast, were measured.
  • Beta-actin was measured as a comparative gene. Also, the memory improvement effect was measured.
  • the lipid peroxidation degree in the large intestine tissue was analyzed by using TBARS analysis kit (Cayman chem., USA). 100 ⁇ l of homogenate of the large intestine tissue was placed in 5 ml of a polypropylene screw-cap centrifugal tube, and then 100 ⁇ l of SDS solution was added and shaken lightly. 4 ml of color reagent was added to the tube, and then put into boiling water for 1 hour to stop the reaction. Thereafter, it was centrifuged for 10 min at 4° C., 13000 rpm, and then allowed to stand for 30 min at the room temperature, and measured the absorbance at 540 nm using an ELISA reader. The standard cure was made by using malonaldehyde (MDA) as a standard material, and the amount of MDA produced from this was measured.
  • MDA malonaldehyde
  • the Cu, Zn-SOD activity was measured by using xanthine oxidase-cytochrome C system.
  • a GSH concentration was measured by diluting a sample with a phosphate buffer and adding o-phthaldehyde, shaking for 15 mM, and measuring the fluorescence at 345 nm of an excitation wavelength and 425 nm of a radiation wavelength.
  • the supernatant was taken and subjected to the electrophoresis in a SDS 10% (w/v) polyacrylamide gel for 1 hr and 30 minutes (sample, 50 ⁇ g).
  • the gel subjected to the electrophoresis was transferred to a nitrocellulose paper at 100 V, 400 mA for 1 hour and 10 minutes, the transferred nitrocellulose paper was blocked with 5% defatted milk for 30 minutes and then was washed with PBS-Tween three times with each of 5 minutes, reacted with the first antibody (Santa Cruz Biotechnology, USA) at 1:100 overnight, washed three times with each of 10 minutes, and reacted with the secondly antibody (Santa Cruz Biotechnology, USA) at 1:1000 for 1 hour and 20 minutes. After then, it was washed three times with each of 15 minutes, was development with emitting fluorescence.
  • a Y-maze task equipment has a shape of alphabet Y extending three arms, wherein the each branch has 25 cm of a length, 14 cm of a height, and 5 cm of a width and placed with the same angle.
  • a head part of the laboratory animal is headed for the end of a path of Y-maze and let it go around the path freely for 8 minutes. After recording a movement of the animal, when hind legs of the animal entered the passage, it is considered that the animal is arm entry.
  • the movement of the animal is represented by alternation, which is defined that when the animal passes three (3) passages continuously, it is defined as one alternation.
  • a spontaneous alternation is represented as a percent of the real alternation and the maximal possible alternation (i.e., a value obtained by deducting 2 from the total alternation).
  • the C29 lactic acid bacteria, C3 lactic acid bacteria and C24 lactic acid bacteria were administered to the mice aged 16 months in 1 ⁇ 10 9 CFU one per 1 day for two (2) days.
  • scopolamine did not administered.
  • the C29 lactic acid bacteria was the best in the memory improvement effect of the aged mouse, and then was in the order of the C3 lactic acid bacteria and C24 lactic acid bacteria.
  • the mouse did not find the platform within 120 sec, it is allowed to stay in the platform for 10 sec, and then finished the trial.
  • a probe test was practiced to the animal that the trial was finished at 24 hrs after the final trial. At this time, the platform was removed from the pool, and the time staying in the 4-divided circle that the platform was placed during 90 sec was measured to represent it as a percentage.
  • a swimming time was measured daily while administering the C29 lactic acid bacteria, C3 lactic acid bacteria and C24 lactic acid bacteria to the mice aged 16 months in the amount of 1 ⁇ 10 9 CFU once per a day for 4 days.
  • scopolamine did not administered.
  • the C29 lactic acid bacteria were the best in the memory improvement effect of the aged mouse, and then were in the order of the C3 lactic acid bacteria and C24 lactic acid bacteria.
  • the soybean fermentation composition fermented by C29 maintained the best in memory for the passive avoidance and exhibited superior effect as compared with the treating agent of dementia, Tacrin (TAC, 10 mg/kg), and followed by the ginseng fermentation composition fermented by C29, soybean fermentation composition fermented by C3, and condonopsis lanceolata fermentation composition fermented by C29 in order. It shows that the fermentation composition fermented by the C29 or C3 strain has the memory improvement effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US14/421,714 2012-08-16 2013-08-16 Lactic acid bacteria capable of preventing and/or treating senescence and dementia Abandoned US20150306158A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0089714 2012-08-16
KR20120089714 2012-08-16
PCT/KR2013/007410 WO2014027864A1 (ko) 2012-08-16 2013-08-16 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/007410 A-371-Of-International WO2014027864A1 (ko) 2012-08-16 2013-08-16 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/297,955 Division US10874701B2 (en) 2012-08-16 2016-10-19 Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US15/641,873 Division US10561691B2 (en) 2012-08-16 2017-07-05 Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US15/641,873 Continuation US10561691B2 (en) 2012-08-16 2017-07-05 Lactic acid bacteria capable of preventing and/or treating senescence and dementia

Publications (1)

Publication Number Publication Date
US20150306158A1 true US20150306158A1 (en) 2015-10-29

Family

ID=50268816

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/421,714 Abandoned US20150306158A1 (en) 2012-08-16 2013-08-16 Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US15/641,873 Active 2033-10-04 US10561691B2 (en) 2012-08-16 2017-07-05 Lactic acid bacteria capable of preventing and/or treating senescence and dementia

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/641,873 Active 2033-10-04 US10561691B2 (en) 2012-08-16 2017-07-05 Lactic acid bacteria capable of preventing and/or treating senescence and dementia

Country Status (6)

Country Link
US (2) US20150306158A1 (ja)
JP (1) JP6009080B2 (ja)
KR (2) KR101476236B1 (ja)
CN (1) CN104781390B (ja)
HK (1) HK1212387A1 (ja)
WO (1) WO2014027864A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226441B2 (en) 2014-12-09 2019-03-12 Nihon Sizen Hakkoh Co., Ltd. Aging inhibitor
US10471111B2 (en) 2015-09-15 2019-11-12 University-Industry Cooperation Group Of Kyung Hee University Lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders
US10561691B2 (en) 2012-08-16 2020-02-18 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
EP3636744A4 (en) * 2017-06-01 2021-03-03 Korea Food Research Institute LACTOBACILLUS CURVATUS WIKIM55, EFFECTIVE TO PROMOTE HAIR GROWTH AND COMPOSITION WITH IT
IT202000007690A1 (it) * 2020-04-09 2021-10-09 Probiotical Spa Uso di ceppi di batteri Lactobacillus plantarum e/o Lactobacillus pentosus nella riduzione di una quantità ingerita o accumulata di fosfonati nel microbiota umano
CN113543659A (zh) * 2019-01-15 2021-10-22 韩国食品研究院 包含意外片球菌的用于预防、改善或治疗神经退行性疾病的组合物
CN113521111A (zh) * 2021-03-16 2021-10-22 浙江大学 青春双歧杆菌在衰老延缓方面的应用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016110768A1 (en) * 2015-01-07 2016-07-14 Ecole Polytechnique Federale De Lausanne (Epfl) Gastro-intestinal biomarkers for diagnosis and therapies of proteinopathies
CN116196340A (zh) * 2016-05-31 2023-06-02 森永乳业株式会社 脑功能改善剂
KR101799830B1 (ko) 2016-06-14 2017-11-21 한국생명공학연구원 퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아가토바쿨룸 속 균주 및 이의 용도
JP6898628B2 (ja) * 2016-06-15 2021-07-07 国立大学法人広島大学 神経変性疾患治療剤
JP6757190B2 (ja) * 2016-06-29 2020-09-16 株式会社ヤクルト本社 危機回避能力低下抑制剤
US20190314425A1 (en) 2016-07-11 2019-10-17 Korea Research Institute Of Bioscience And Biotechnology Akkermansia muciniphila strain having a prophylactic or therapeutic effect on a degenerative brain disease or metabolic disease and use thereof
WO2018043874A1 (ko) * 2016-08-30 2018-03-08 (주)코엔바이오 지방 분해능을 갖는 균주를 포함하는 탈모 방지 또는 발모 촉진용 조성물
CN106399163B (zh) * 2016-09-08 2019-09-27 江苏微康生物科技有限公司 一种抗衰老益生菌制剂及制备方法
CN106858606B (zh) * 2016-12-28 2020-12-11 石家庄君乐宝乳业有限公司 具有抗氧化功能的益生菌粉及其制备方法
CN108048342B (zh) * 2017-10-26 2021-06-04 中国农业大学 一种耐压益生菌及其食品和制备方法
KR101972236B1 (ko) 2017-11-02 2019-04-24 서원대학교산학협력단 김치에서 분리한 락토바실러스 플란타룸 및 이의 용도
CN109182162B (zh) * 2018-08-17 2021-10-26 哈尔滨美华生物技术股份有限公司 一株具有抗氧化能力的植物乳杆菌及应用
CN110499263B (zh) * 2019-07-12 2020-10-30 华东理工大学 一种植物乳杆菌x7022及其应用
JP6739602B1 (ja) * 2019-07-24 2020-08-12 雪印メグミルク株式会社 記憶・学習能維持および／または向上用組成物及び組成物を含む食品、医薬品、飼料
JP6739603B1 (ja) * 2019-07-24 2020-08-12 雪印メグミルク株式会社 記憶・学習能維持および／または向上用組成物及び組成物を含む食品、医薬品、飼料
KR20210055477A (ko) 2019-11-07 2021-05-17 주식회사 에치와이 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물
KR102133721B1 (ko) * 2019-12-12 2020-07-14 신연희 감 잎 발효물을 포함하는 항산화 효과를 갖는 기능성 식품 조성물
JP2021020885A (ja) * 2020-03-09 2021-02-18 雪印メグミルク株式会社 記憶・学習能維持および／または向上用組成物及び組成物を含む食品、医薬品、飼料
KR102404659B1 (ko) 2020-09-23 2022-06-07 주식회사 에치와이 락토바실러스 파라카제이 hp7 균주를 함유하는 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물
KR102404658B1 (ko) 2020-09-23 2022-06-07 주식회사 에치와이 락토바실러스 카제이 hy2782 균주를 함유하는 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물
KR102404656B1 (ko) 2020-09-23 2022-06-07 주식회사 에치와이 비피도박테리움 애니멀리스 서브스페시스 락티스 hy8002균주를 함유하는 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물
KR102404657B1 (ko) 2020-09-23 2022-06-07 주식회사 에치와이 락토바실러스 플란타룸 hy7715균주를 함유하는 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물
KR20220040017A (ko) * 2020-09-23 2022-03-30 주식회사 프로바이오닉 락토바실러스 사케이 Probio-65를 포함하는 알츠하이머병의 예방 또는 치료용 조성물
CN112111430B (zh) * 2020-09-27 2022-10-21 吉林农业大学 一种抗氧化与抗衰老双效益生菌及其应用
WO2022092919A1 (ko) 2020-10-29 2022-05-05 엠테라파마 주식회사 신규한 비피도박테리움 롱검 z1 균주 및 이의 용도
CN112386614B (zh) * 2020-11-25 2022-11-08 天津科技大学 植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用
KR102480131B1 (ko) * 2020-12-14 2022-12-23 서울대학교산학협력단 인지능력 개선 기능을 가지는 락토바실러스 람노수스
KR102480146B1 (ko) * 2020-12-14 2022-12-23 서울대학교산학협력단 인지능력 개선 기능을 가지는 락토바실러스 아시도필루스
KR102480136B1 (ko) * 2020-12-14 2022-12-23 서울대학교산학협력단 인지능력 개선 기능을 가지는 락토바실러스 파라카제이
KR102572025B1 (ko) 2021-02-02 2023-08-29 단국대학교 천안캠퍼스 산학협력단 신규한 류코노스톡 메젠테로이드 mkjw 균주 및 이의 용도
KR20230085279A (ko) 2021-12-06 2023-06-14 엠테라파마 주식회사 락토바실러스 파라카제이 nk112, 실새삼 추출물 및 새삼 추출물을 포함하는 인지기능 및 장기능 장애의 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440426B2 (en) * 2007-04-18 2013-05-14 Kigen Biogenics Institute Co., Ltd. Method for production of antimutagenic substance using lactic acid bacterium

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619005B2 (en) 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
PL363426A1 (en) * 2001-03-09 2004-11-15 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
KR100503925B1 (ko) * 2001-07-31 2005-07-27 김종덕 항산화성을 갖는, 장내 세균 성장촉진용 조성물
JP4119656B2 (ja) * 2002-02-28 2008-07-16 雪印乳業株式会社 抗酸化剤
CN1511520A (zh) 2002-12-31 2004-07-14 �й�ҽѧ��ѧԺҩ���о��� 丁二酸酯衍生物治疗痴呆症的用途
KR20070070153A (ko) * 2004-06-23 2007-07-03 로레알 민감성 및/또는 건성 피부의 예방 및/또는 치료에 유용한방법 및 조성물
JP2007126399A (ja) * 2005-11-04 2007-05-24 Suntory Ltd グルタチオン増加用組成物
KR100847104B1 (ko) * 2005-11-24 2008-07-18 문상욱 아토피 피부염 개선제 조성물
HUP0700552A2 (en) * 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
KR101010914B1 (ko) * 2008-04-28 2011-01-26 주식회사 엔유씨전자 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄
CN102395371A (zh) 2009-04-13 2012-03-28 施万制药 用于治疗认知障碍的5-ht4受体促效剂化合物
JP5667358B2 (ja) 2009-06-03 2015-02-12 富士産業株式会社 柑橘類果皮の麹菌発酵組成物
JP5155961B2 (ja) * 2009-07-17 2013-03-06 雪印メグミルク株式会社 加齢に伴う代謝異常症の予防・改善・治療剤
KR101087972B1 (ko) * 2009-11-24 2011-12-01 일동제약주식회사 치매, 치매관련 질환의 예방/치료 및 인지기능장애 개선에 효과가 있는 유산균 발효 산물, 이의 제조방법 및 용도
US8257761B2 (en) * 2009-12-15 2012-09-04 Jacob Ludwig Manfred Polyphenol-containing products
EP2515937B1 (en) * 2009-12-22 2019-10-23 Probi AB Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof
CN104781390B (zh) 2012-08-16 2017-07-28 庆熙大学校产学协力团 具有对衰老及痴呆的预防和/或治疗活性的乳酸菌
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440426B2 (en) * 2007-04-18 2013-05-14 Kigen Biogenics Institute Co., Ltd. Method for production of antimutagenic substance using lactic acid bacterium

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Jung et al., Journal of Applied Microbiology Vol. 113, pages 1498-1506, 2012. *
Mendiola-Precoma et al., BioMed Research International, Volume 2016, Article ID 2589276, 17 pages. *
Nedelcheva et al., (2010), Biotechnology & Biotechnological Equipment, 24:1, 1624-1630. *
Virtanen et al., .(Journal of Applied Microbiology, Vol. 102 (2007), pages 106–115 *
Wang et al., Asian-Aust. Ja. Anim. Sci., Vol. 25, pages 1153-1158, 2012. *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561691B2 (en) 2012-08-16 2020-02-18 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US10226441B2 (en) 2014-12-09 2019-03-12 Nihon Sizen Hakkoh Co., Ltd. Aging inhibitor
US10471111B2 (en) 2015-09-15 2019-11-12 University-Industry Cooperation Group Of Kyung Hee University Lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders
US11202811B2 (en) 2015-09-15 2021-12-21 University-Industry Cooperation Group Of Kyung Hee University Lactobacillus having various functions, and use thereof
US11771725B2 (en) 2015-09-15 2023-10-03 University-Industry Cooperation Group Of Kyung Hee University Lactobacillus having various functions, and use thereof
EP3636744A4 (en) * 2017-06-01 2021-03-03 Korea Food Research Institute LACTOBACILLUS CURVATUS WIKIM55, EFFECTIVE TO PROMOTE HAIR GROWTH AND COMPOSITION WITH IT
US11559064B2 (en) 2017-06-01 2023-01-24 Korea Food Research Institute Lactobacillus curvatus WIKIM55 having activity of promoting hair growth, and composition containing same
CN113543659A (zh) * 2019-01-15 2021-10-22 韩国食品研究院 包含意外片球菌的用于预防、改善或治疗神经退行性疾病的组合物
IT202000007690A1 (it) * 2020-04-09 2021-10-09 Probiotical Spa Uso di ceppi di batteri Lactobacillus plantarum e/o Lactobacillus pentosus nella riduzione di una quantità ingerita o accumulata di fosfonati nel microbiota umano
WO2021205395A1 (en) * 2020-04-09 2021-10-14 Probiotical S.P.A. Use of bacterial strains lactobacillus brevis, lactobacillus plantarum and/or lactobacillus pentosus in the reduction of an ingested or accumulated amount of phosphonates in the human microbiota
CN113521111A (zh) * 2021-03-16 2021-10-22 浙江大学 青春双歧杆菌在衰老延缓方面的应用

Also Published As

Publication number Publication date
JP2015526085A (ja) 2015-09-10
CN104781390B (zh) 2017-07-28
KR20140023241A (ko) 2014-02-26
KR101476236B1 (ko) 2014-12-24
KR20140131894A (ko) 2014-11-14
US20170368114A1 (en) 2017-12-28
HK1212387A1 (en) 2016-06-10
WO2014027864A1 (ko) 2014-02-20
JP6009080B2 (ja) 2016-10-19
CN104781390A (zh) 2015-07-15
US10561691B2 (en) 2020-02-18

Similar Documents

Publication Publication Date Title
US10561691B2 (en) Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US10874701B2 (en) Lactic acid bacteria capable of preventing and/or treating senescence and dementia
JP7012840B2 (ja) 乳酸菌及びその用途
TWI696465B (zh) 新穎乳酸菌及其用途
US20180207165A1 (en) Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
JP5791009B2 (ja) 乳酸菌およびそれらを用いた飲食物又は化粧品
CN112204129A (zh) 植物乳杆菌kbl396菌株及其用途
Kumari et al. Clinical importance of lactic acid bacteria: a short review
KR20110000871A (ko) 항산화 및 항염증 효능을 갖는 락토바실러스 플란타룸 에이취와이7711 및 이를 유효성분으로 함유하는 제품
JP6894097B2 (ja) 腎性貧血改善用組成物
JP7060555B2 (ja) ビフィドバクテリウムラクティスｇｋｋ２の活性物質、それを含む組成物及びそれによって長寿命化を促進する方法
JP5740613B2 (ja) 疾患の予防改善剤、持久力向上剤、抗疲労剤、並びにそれらを用いた医薬品および飲食品
Samedi et al. Evaluation of technological and probiotic abilities of local lactic acid bacteria
KR20200084829A (ko) 나노화된 김치 유산균을 함유하는 항바이러스용 약학조성물
TWI829090B (zh) 抗憂鬱劑、抗老化劑及抗肥胖劑
KR20180110848A (ko) 신규한 락토바실러스 루테리 균주 및 그 프로바이오틱 용도
Polyanskaya et al. Bio-elements in functional foods.
Pophaly et al. Functional Starter Cultures for Fermented Dairy Products
CN103562381B (zh) 缺失d-乳酸产生并且具有改进的贮藏期限的约氏乳杆菌菌株cncm i-1225的衍生物
Chauhan Screening of potential probiotic lactic acid bacteria from fresh water fish intestine
KR100630907B1 (ko) 락토바실러스 스포러제네스 씨유 4109
KR100630906B1 (ko) 락토바실러스 카세이 씨유 4114
Fuchs et al. and Siegfried Knasmüller
Saito et al. Viability and resistance to simulated gastrointestinal digestion of lactobacilli strains isolated from spontaneous cocoa fermentation in fermented soybean milk along storage

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, DONG-HYUN;HAN, MYUNG JOO;JUNG, IL-HOON;AND OTHERS;SIGNING DATES FROM 20150210 TO 20150216;REEL/FRAME:035009/0434

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION